Genmab spent more than DKK 1 billion in Q1

Genmab's research and development projects have been costly in the first quarter, but the Danish biotech firm's profit has quadrupled. It maintains its guidance.

Photo: Joost Melis / Genmab / PR

The first quarter of the year has gone according to plan for the Danish biotech firm Genmab.

Research and development (R&D) activities have been especially busy, and the firm has posted a sizeable amount of money into the continued expansion of the organization.

Read the whole article

Get 14 days free access.
No credit card required.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Orphazyme cuts guidance following FDA setback

Friday's disappointing rejection letter from the US FDA is affecting Orphazyme's guidance for 2021. Now, the biotech firm forecasts an operating deficit of DKK 670-700m, up from DKK 100-150m.

Further reading

Related articles

Latest news

See all jobs